Anixa Biosciences Inc represents a strong commitment to advanced cancer diagnostics and therapeutics. The company's corporate philosophy revolves around leveraging groundbreaking technologies and innovative approaches to improving patient outcomes in the field of oncology. Anixa believes in the power of precision medicine, striving to develop and commercialize highly accurate and personalized diagnostic tests that can detect cancers at early stages, allowing for more effective treatments. By harnessing the potential of artificial intelligence and bioinformatics, Anixa is dedicated to revolutionizing cancer care and enhancing the quality of life for cancer patients worldwide.

Anixa Biosciences Inc primarily operates in the United States.

Anixa Biosciences Inc has achieved significant milestones in its journey. The company has made notable advancements in the field of biosciences, contributing to groundbreaking research and development. With its unwavering commitment to innovation, Anixa Biosciences Inc has successfully launched several cutting-edge products and services. Additionally, the company has received recognition for its remarkable achievements, including prestigious awards and accolades within the industry. These milestones speak volumes about Anixa Biosciences Inc's dedication to pushing the boundaries of scientific exploration and its continued commitment to driving advancements in the biosciences sector.

Anixa Biosciences Inc. is a biotechnology company based in the United States. Founded in 1982, the company has a rich history of innovation and breakthroughs in the field of cancer diagnostics and therapeutics. With a strong focus on cutting-edge technologies, Anixa Biosciences has developed proprietary platforms and systems to detect and treat cancer at an early stage. The company has been involved in numerous research collaborations with leading academic institutions, further strengthening its position as a leader in the biotech industry. With a dedicated team of scientists and experts, Anixa Biosciences continues to make significant strides in improving cancer detection and treatment for the benefit of patients worldwide.

The main competitors of Anixa Biosciences Inc in the market include companies such as Guardant Health, Exact Sciences Corporation, and Foundation Medicine. These companies are also engaged in molecular diagnostics and cancer testing, providing innovative solutions for early detection and personalized medicine. However, Anixa Biosciences sets itself apart through unique technology platforms and partnership collaborations to develop cutting-edge diagnostics and therapeutic treatments in various areas, including liquid biopsy, artificial intelligence, and immuno-oncology.

Anixa Biosciences Inc is primarily active in the biotechnology and healthcare industries.

The business model of Anixa Biosciences Inc is focused on developing and commercializing innovative diagnostics and therapeutics to address unmet needs in the field of cancer. The company's approach involves leveraging cutting-edge technologies such as artificial intelligence, machine learning, and computational biology to identify novel biomarkers and therapeutic targets. By utilizing these advanced technologies, Anixa aims to enhance early cancer detection, improve treatment outcomes, and ultimately save lives. Through strategic partnerships and collaborations, Anixa Biosciences Inc is dedicated to transforming the way cancer is diagnosed and treated.

P/E odnos Anixa Biosciences iznosi -5,54.

KUV kompanije Anixa Biosciences iznosi 0.

AlleAktien kvalitativni skor za Anixa Biosciences je 1/10.

Prihod trenutno ne može biti izračunat za Anixa Biosciences.

Dobit očekivana Anixa Biosciences je -14,04 mil. USD.

Anixa Biosciences Inc is a biotechnology company specializing in the development of products for the diagnosis, treatment, and prevention of cancer. The company is headquartered in San Jose, California, USA and was founded in 1982. Anixa Biosciences specializes in four different business areas: diagnostics, therapeutics, vaccines, and oncology. In the diagnostics field, the company offers tests for various types of cancer. These diagnostic tests are based on proprietary technologies such as liquid biopsy technology and the CchekTM prostate cancer tumor DNA test. In the therapeutics field, Anixa Biosciences has developed various cellular therapies focused on immunotherapy. This involves directing immune cells against cancer cells to destroy them. The company is also working on the development of RNAi therapeutics that can suppress the expression of certain genes in cancer cells. In the vaccines field, Anixa Biosciences is developing vaccines against various types of cancer. The main focus is on the development of cancer vaccines that stimulate the immune system to recognize and destroy cancer cells. In the oncology field, Anixa Biosciences offers products and services that support researchers, clinics, and pharmaceutical companies focused on the discovery of new cancer therapies. The products and services of Anixa Biosciences are based on proprietary technologies such as the NexGenTM platform, which allows for rapid and accurate cancer diagnosis. This technology also utilizes machine learning and artificial intelligence to further improve cancer diagnosis. Anixa Biosciences has partnerships with various players in the healthcare and biotechnology industries to market its innovative products and services. The company also utilizes patented technologies to protect the exclusivity of its products and services. Overall, Anixa Biosciences' business model enables the development and marketing of innovative products and services that contribute to the diagnosis, treatment, and prevention of cancer. The company specializes in various sectors and utilizes proprietary technologies to strengthen its market position.

Anixa Biosciences isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Anixa Biosciences trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Anixa Biosciences je US03528H1095.

WKN od Anixa Biosciences je A2N6ZF.

Oznaka za praćenje akcija kompanije Anixa Biosciences je ANIX.

U poslednjih 12 meseci, Anixa Biosciences je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Anixa Biosciences će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Anixa Biosciences trenutno iznosi .

Anixa Biosciences isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Anixa Biosciences je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Anixa Biosciences se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Anixa Biosciences od 13. 7. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 13. 7. 2024..

Isplata poslednje dividende izvršena je 13. 7. 2024..

U godini 2023 kompanija Anixa Biosciences je isplatila 0 USD kao dividende.

Dividende od Anixa Biosciences se isplaćuju u USD.